BRAF and melanoma: Similarly, in patients with BRAF-mutant melanoma, one retrospective study found that 90 patients taking BRAF inhibitors were 30% more likely than a chemotherapy comparator group to develop IMD, although these results were not significant (p = 0.5129), nor did the study report data comparing OS in patients without IMD (14).